ClinicalTrials.gg
RecruitingNCT06822998HF50Updated Aug 17, 2025

HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors

An Early Phase 1 interventional study of HF50 in Advanced Solid Tumors, sponsored by HighField Biopharmaceuticals Corporation. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-17.

Sponsored by HighField Biopharmaceuticals Corporation · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, single-arm, non-randomized, single-center, dose-escalation study designed to evaluate the safety and tolerability of HF50 in patients with HER-2 positive and HER-2 low-expression advanced solid tumors. The primary objectives are to assess the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of HF50. Secondary objectives include evaluating the pharmacokinetic (PK) profile and preliminary antitumor activity of HF50.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

HighField Biopharmaceuticals Corporation is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must voluntarily provide written (ICF) prior to any study-related procedures, and be capable of complying with all protocol requirements.
  • Adult participants aged between 18 and 75 years (inclusive) at the time of ICF signing.
  • or cytologically confirmed advanced positive or HER-2 low-expression solid tumors that are unresectable, , or have after standard therapies, are intolerant to standard therapies (e.g., chemotherapy, targeted therapy), or lack effective treatment options.
  • (ECOG) performance status of 0 or 1.
  • of at least 3 months.
  • At least one as defined by version 1.1.
  • Adequate organ and bone marrow function as demonstrated by the following laboratory parameters:Hematologic Function: (ANC) ≥1.5×10⁹/L、Lymphocyte count ≥1.0×10⁹/L、 count ≥90×10⁹/L、 ≥9.0 g/dL (without transfusion or erythropoietin-stimulating agents within 14 days); Coagulation Parameters: (aPTT) ≤1.5×、 International normalized ratio (INR) ≤1.5. Hepatic Function:Total (TBIL) ≤1.5×ULN、 (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN for participants with liver metastases, and TBIL ≤3×ULN); Renal Function: (CrCl) ≥50 mL/min (Cockcroft-Gault formula).
  • Female participants of must have a negative serum pregnancy test at screening and prior to the first dose. Male and female participants of childbearing potential must agree to use effective during the study and for 6 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • History of active disease or autoimmune disease considered unsuitable for study participation, with exceptions for localized skin conditions (e.g., eczema involving \<10% of body surface area, vitiligo, psoriasis, alopecia) or childhood asthma resolved without treatment in adulthood.
  • Current use of or systemic (>10 mg/day prednisone or equivalent) within 4 weeks prior to the first dose, except for local steroid use.
  • Receipt of systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy less than 2 weeks (or 4 weeks for nitrosourea or mitomycin C) or within 5 half-lives of the prior therapy before the first dose.
  • Symptomatic or unless adequately treated (e.g., surgery or radiotherapy) with no evidence of progression for ≥28 days and off systemic steroids for ≥14 days prior to the first dose.
  • Unresolved toxicities from prior therapies ≥Grade 2 ( v5.0) at baseline, except for toxicities deemed by the investigator to pose no safety risk (e.g., alopecia, stable hypothyroidism with hormone replacement).
  • Significant cardiovascular or cerebrovascular conditions, including but not limited to:Thromboembolic events requiring therapeutic anticoagulation within 3 months prior to the first dose. Class III or IV heart failure.Acute coronary syndrome, congestive heart failure, aortic dissection, or stroke within 6 months prior to the first dose.Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg), unless controlled with antihypertensive medication.
  • Active infection or unexplained fever >38.5°C within 1 week prior to the first dose (tumor-related fever may be eligible at the investigator's discretion).
  • Known infection, active virus (HBV) infection (HBV DNA >), or active virus (HCV) infection (HCV RNA >ULN).
  • Gastrointestinal symptoms or other conditions requiring intervention within 4 weeks prior to the first dose that would, in the investigator's judgment, impair study participation.
  • Pregnant or breastfeeding women.
  • Any other severe systemic disease, psychological condition, or significant clinical abnormality deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Dose Level 1 - 1 mg

    Participants in this arm will receive HF50 via intravenous infusion once weekly for 3 weeks in a 3-week treatment cycle. The dose is 1 mg, with a lead-in dose on Cycle 1 Day 1 (C1D1) followed by the target dose on C1D8, C1D15, and C1D22.

    Drug: HF50

  • Experimental
    Dose Level 2 - 10 mg

    Participants in this arm will receive HF50 via intravenous infusion once weekly for 3 weeks in a 3-week treatment cycle. The dose is 10 mg, with a lead-in dose on C1D1 followed by the target dose on C1D8, C1D15, and C1D22.

    Drug: HF50

  • Experimental
    Dose Level 3 - 60 mg

    Participants in this arm will receive HF50 via intravenous infusion once weekly for 3 weeks in a 3-week treatment cycle. The dose is 60 mg, with a lead-in dose on C1D1 followed by the target dose on C1D8, C1D15, and C1D22.

    Drug: HF50

  • Experimental
    Dose Level 4 - 240 mg

    Participants in this arm will receive HF50 via intravenous infusion once weekly for 3 weeks in a 3-week treatment cycle. The dose is 240 mg, with a lead-in dose on C1D1 followed by the target dose on C1D8, C1D15, and C1D22.

    Drug: HF50

Interventions

  • DrugHF50

    HF50 is a liposomal T-cell engager with an unique design based on the lipid bilayer. It was also named a T cell Redirecting Antibody Fragment-anchored Liposomes (TRAFsome). The liposomal surface carries anti-CD3ε and anti-HER2 antibody-conjugated lipid molecules, enabling T-cell redirection and activation at HER2-positive or HER2-low tumor sites. In addition, the liposome internal space contains a TLR7/8 agonist Resiquimod (R848), which has been shown to help modulate the myeloid cells in the tumor micro-environement to complement the immune activation effects.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLT)

    The number of participants experiencing dose-limiting toxicities (DLTs) during the DLT evaluation period to determine the maximum tolerated dose (MTD).

    Time frame: 28 days after the first dose (C1D1) for each dose cohort.

  2. Incidence of Adverse Events (AEs)

    The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0

    Time frame: From first dose to 28 days after the last dose.

  3. Incidence of Serious Adverse Events (SAEs)

    The number and percentage of participants experiencing adverse events (AEs), graded according to NCI-CTCAE v5.0.

    Time frame: From first dose to 28 days after the last dose.

  4. Recommended Phase II Dose (RP2D) of HF50

    RP2D will be determined based on safety, tolerability, and pharmacokinetics data collected during the dose escalation phase.

    Time frame: At the end of dose escalation (assessed up to 1 year)

  5. Incidence of Vital Sign Abnormalities

    Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline vital sign abnormality, including blood pressure, heart rate, respiratory rate, and body temperature. Grades are defined using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

    Time frame: From first dose to the end of the study (assessed up to 1 year)

  6. Laboratory Abnormalities

    Number of participants who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including hematology (complete blood count), blood chemistry, urinalysis, coagulation function, and C-reactive protein (CRP). Grades are defined using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

    Time frame: From first dose to the end of the study (assessed up to 1 year)

  7. Incidence of Electrocardiogram (ECG) Abnormalities

    Number of participants who experienced an abnormal ECG finding post-baseline, including clinically significant changes in QT interval, PR interval, QRS duration, or other rhythm abnormalities as assessed by 12-lead ECG. Abnormalities will be graded according to National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

    Time frame: From first dose to the end of the study (assessed up to 1 year)

  8. Incidence of Echocardiography (ECHO) Abnormalities

    Number of participants who experienced an abnormal echocardiography finding post-baseline, including changes in left ventricular ejection fraction (LVEF), chamber size abnormalities, or valvular dysfunction. Abnormalities will be graded according to CTCAE v5.0.

    Time frame: From first dose to the end of the study (assessed up to 1 year)

Secondary outcomes

  1. Pharmacokinetic Parameter - Cmax

    Maximum plasma concentration (Cmax) of HF50 will be assessed following single and multiple dosing.

    Time frame: Up to 9 weeks

  2. Pharmacokinetic Parameter - Tmax

    Time to maximum plasma concentration (Tmax) of HF50 will be assessed following single and multiple dosing.

    Time frame: Up to 9 weeks

  3. Pharmacokinetic Parameter - AUC (Area Under the Curve)

    AUC0-t and AUC0-inf will be evaluated to determine systemic exposure to HF50.

    Time frame: Up to 9 weeks

  4. Pharmacokinetic Parameter - Half-life (t1/2)

    The terminal elimination half-life (t1/2) of HF50 will be calculated.

    Time frame: Up to 9 weeks

  5. Objective Response Rate (ORR)

    Proportion of participants achieving a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria.

    Time frame: Up to 2 years

  6. Duration of Response (DOR)

    Time from the first documented response (CR or PR) to disease progression or death.

    Time frame: Up to 2 years

  7. Disease Control Rate (DCR)

    Proportion of participants achieving CR, PR, or stable disease (SD) based on RECIST v1.1.

    Time frame: Up to 2 years

  8. Progression-Free Survival (PFS)

    Time from the first dose to disease progression or death.

    Time frame: Up to 2 years

  9. Overall Survival (OS)

    Time from the first dose to death from any cause.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Mar 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2025
First posted
Feb 12, 2025
StartActual
Jun 11, 2025
Primary completionEst.
Mar 1, 2026
CompletionEst.
Jun 1, 2026
Last update
Aug 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06822998
Lead sponsor
HighField Biopharmaceuticals Corporation
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Jun 11, 2025
Primary completion
Mar 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
Aug 17, 2025

Study contacts

Zelei Dai, MMedSc
Contact
daisydzl@icloud.com
+86 17691161216
Lei Liu, MD, PhD
principal investigator · West China Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion